How to translate text using browser tools
18 November 2019 Impact of the PrC-210 Radioprotector Molecule on Cancer Deaths in p53-Deficient Mice
William E. Fahl, Frank Jermusek, Thomas Guerin, Dawn M. Albrecht, Carol J. Sarabia Fahl, Emma Dreischmeier, Chelsea Benedict, Susan Back, Jens Eickhoff, Richard B. Halberg
Author Affiliations +
Abstract

Radiation-induced cancer is an ongoing and significant problem, with sources that include clinics worldwide in which 3.1 billion radiology exams are performed each year, as well as a variety of other scenarios such as space travel and nuclear cleanup. These radiation exposures are typically anticipated, and the exposure is typically well below 1 Gy. When radiation-induced (actually ROS-induced) DNA mutation is prevented, then so too are downstream radiation-induced cancers. Currently, there is no protection available against the effects of such <1 Gy radiation exposures. In this study, we address whether the new PrC-210 ROS-scavenger is effective in protecting p53-deficient (p53–/–) mice against X-ray-induced accelerated tumor mortality; this is the most sensitive radiation tumorigenesis model currently known. Six-day-old p53–/– pups received a single intraperitoneal PrC-210 dose [0.5 maximum tolerated dose (MTD)] or vehicle, and 25 min later, pups received 4.0 Gy X-ray irradiation. At 5 min postirradiation, blood was collected to quantify white blood cell c-H2AX foci. Over the next 250 days, tumor-associated deaths were recorded. Findings revealed that when administered 25 min before 4 Gy X-ray irradiation, PrC-210 reduced DNA damage (c-H2AX foci) by 40%, and in a notable coincidence, caused a 40% shift in tumor latency/incidence, and the 0.5 MTD PrC210 dose had no discernible toxicities in these p53–/– mice. Essentially, the moles of PrC-210 thiol within a single 0.5 MTD PrC-210 dose suppressed the moles of ROS generated by 40% of the 4 Gy X-ray dose administered to p53–/– pups, and in doing so, eliminated the lifetime leukemia/lymphoma risk normally residing “downstream” of that 40% of the 4 Gy dose. In conclusion: 1. PrC-210 is readily tolerated by the 6-day-old p53–/– mice, with no discernible lifetime toxicities; 2. PrC-210 does not cause the nausea, emesis or hypotension that preclude clinical use of earlier aminothiols; and 3. PrC-210 significantly increased survival after 4 Gy irradiation in the p53–/– mouse model.

©2020 by Radiation Research Society. All rights of reproduction in any form reserved.
William E. Fahl, Frank Jermusek, Thomas Guerin, Dawn M. Albrecht, Carol J. Sarabia Fahl, Emma Dreischmeier, Chelsea Benedict, Susan Back, Jens Eickhoff, and Richard B. Halberg "Impact of the PrC-210 Radioprotector Molecule on Cancer Deaths in p53-Deficient Mice," Radiation Research 193(1), 88-94, (18 November 2019). https://doi.org/10.1667/RR15439.1
Received: 21 May 2019; Accepted: 21 October 2019; Published: 18 November 2019
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top